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ABSTRACT 
Objective: Few studies have been conducted in Kentucky to investigate the statewide 
prevalence of HCV infection and its associated risk factors. The purpose of this study was 
to examine the factors related to HCV infection in the state, and specifically to investigate 
geographical differences of HCV infection between those residing in Appalachian vs. Non-
Appalachian counties in Kentucky. 
Methods: The study sample (n =5205) was selected from a pool of 8300 high-risk 
individuals participating in a pilot cross-sectional study on HCV conducted by the 
Kentucky Department for Public Health. The pilot study involved serologically testing 
participants for antibodies against HCV infection and having participants complete an 
interview-administered questionnaire at the same time to examine behavioral and socio-
demographic characteristics related to HCV infection. Univariate, bivariate, and logistic 
regression analyses were carried out using SPSS and maps were produced using ArcGIS 
software. Frequency distribution, adjusted odds ratios (AORs), and corresponding 95% 
confidence intervals (95% CIs) were reported. 
Results: Of the 5205 participants selected (2241 males, 2964 females; mean age, 
30.4 ± 10.5 years); 9.8% tested positive for anti-HCV antibodies. Residence in 
Appalachian vs. Non-Appalachian Kentucky was not significantly associated with HCV 
antibody status. In the multivariate analysis, Blacks (AOR: 0.42, 95% CI: 0.26 – 0.66) and 
men who have sex with men (MSM) (AOR: 0.36, 95% CI: 0.17 – 0.73) were significantly 
less likely to be HCV positive after adjusting for all other variables. HCV seropositivity 
was positively associated with age (AOR: 1.03, 95% CI: 1.02 – 1.04), history of injection 
drug use (IDU) (AOR: 41.27, 95% CI: 31.94 – 53.31), and presence of tattoos (AOR: 1.49, 
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95% CI: 1.14 – 1.96). Gender was also found to significantly modify the association 
between residence and HCV antibody status, specifically in the Appalachian region. 
Conclusion: This was the first statewide analysis to examine the prevalence of HCV 
infection among high-risk population residing in Appalachia vs. Non-Appalachian counties 
in Kentucky. The main variables associated with HCV infection in these regions were age, 
Black race, history of IDU, MSM and presence of tattoos. Addressing these risky behaviors 
and particular populations through age- and gender-specific preventive and treatment 
measures may reduce the high prevalence of HCV infection in the state of Kentucky. 
However, more research is required to further characterize HCV-related risk factors with 
respect to residence in Appalachian vs. Non-Appalachian to determine how these measures 
can be effectively implemented.  
 
Keywords: Hepatitis C virus; Kentucky; injection drug use; Appalachian vs. Non-
Appalachian residence 
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INTRODUCTION 
An estimated 1.6%, roughly 4.1 million of the United States (US) population is 
affected by Hepatitis C virus (HCV) infection (Armstrong et al., 2006; Kramer et al., 2010). 
Approximately 80% of this population is chronically infected with HCV, which equates to 
over 3.2 million people (Armstrong et al., 2006); three-quarters of whom were born during 
1945 through 1965 (CDC, 2015). National surveillance data from 2013 indicate an 
incidence rate of 0.7 cases per 100,000 in the US (CDC, 2015). The highest incidence was 
observed among people 20 to 29 years of age (CDC, 2015). In 2013, 19,368 deaths were 
attributed to HCV-related events in the US (CDC, 2015). 
Approximately three-quarters of people infected with HCV are asymptomatic (CDC, 
2015). Symptoms, if present, are nonspecific. The acute phase of HCV infection, which is 
defined by laboratory confirmation, is short-term and those infected present either with no 
symptoms or mild symptoms including jaundice and/or elevated alanine aminotransferase 
greater than 400 IU/L (Suryaprasad, 2014). Of those infected, over 40-50% recover 
spontaneously and the rest progress into a chronic phase of the infection. Untreated HCV 
infection persists for 20-30 years resulting in advanced liver disease (Zignego et al., 2012). 
This includes liver fibrosis, cirrhosis, liver failure, and ultimately hepatocellular carcinoma 
(El-Serag and Mason, 2000; Thomas and Seeff, 2005). Currently, HCV is the most 
common cause of chronic liver disease and leading cause of liver transplantation in the US 
(Alter, 2007; Gordon et al., 2009; Rustgi, 2007; Searson et al., 2014). 
The predominant route of HCV transmission in the US is percutaneous exposure to 
contaminated blood and other blood products. Populations identified at risk for HCV 
infection include injection drug users (IDU) and occupational exposure to blood via 
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needlestick injuries, those undergoing invasive medical procedures, the homeless 
population, men who have sex with men (MSM), those with human immunodeficiency 
virus (HIV), inmates in correctional facilities, persons born between 1945 and 1965, and 
people who misused alcohol (Alter, 2007; CDC, 2015; Missiha et al., 2008; Searson et al., 
2014). HCV infection is not efficiently transmitted via sex. However, engaging in rough 
sex, sex with multiple sexual partners, and engaging in high-risk sexual practices such as 
unprotected anal sex among MSM, are associated with increased risk of HCV infection 
(CDC, 2015; McFaul et al., 2014).  
The implementation of universal precautions to prevent transmission of blood-borne 
infections by different establishments including hospitals has resulted in a progressive 
decline in the incidence of acute HCV infection in the US (CDC 2015; CDC, 1988). Yet, 
state surveillance data reports from 2006-2012 obtained from NNDSS (2014) revealed 
significant increases in cases of acute HCV infection for Kentucky, Tennessee, Virginia, 
and West Virginia. In 2012, these three states accounted for an estimated 20.4% of acute 
HCV cases reported, with 4.1 cases per 100,000 reported in Kentucky alone compared to 
the national rate of 0.7 cases per 100,000 (CDC, 2015). These data show a drastic increase 
of acute HCV infection in Kentucky to 4.1 cases per 100,000 from 0.7 cases per 100,000 
reported by the state in 2007 (CDC, 2015). Notably, many Kentuckians are likely unaware 
of their HCV infection status due to most infections being asymptomatic as well as the lack 
of available resources for screening and testing high-risk individuals throughout the state.  
Previous studies have focused on assessing the association between several risk 
factors and HCV infection mostly in rural Appalachian regions in Kentucky. The rate of 
HCV infection in Appalachian Kentucky has been found to be strongly associated with 
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IDU (Christian et al., 2010). According to Havens and colleagues (2013) the prevalence of 
HCV infection among people who inject drugs (PWID) in Appalachian Kentucky was 
estimated at 54.6%, which was similar to results from other smaller studies in the region 
(Christian et al., 2010) and national data (Armstrong et al., 2006). Havens and colleagues 
(2013) also identified several factors associated with HCV infection including herpes 
simplex virus 2 (HSV-2), injection of cocaine, injection of prescription opioids, injecting 
for at least 5 years, posttraumatic stress disorder, and recent sharing of syringes. These risk 
factors such as injecting drugs have also been associated with active HCV infection (HCV 
RNA positivity) (Young et al., 2012).  
Research has shown than the high rates of HCV infection can be observed in young 
PWID, predominantly White adults, residing in or near Appalachian jurisdictions 
(Suryaprasad et al., 2014). This study demonstrated that the incidence of acute HCV 
infection in the US was highest in those less than 30 years of age residing in rural areas 
east of the Mississippi River in five states, among which, Kentucky had the highest rate. 
Results from Suryaprasad and colleagues (2014), and Zibbell and colleagues (2015) 
indicated the rates of HCV infection to be more than double amongst young PWID less 
than 30 years of age, residing in or near Appalachian regions compared to young PWID 
residing in Non-Appalachian urban areas.  
This study seeks to further explore the Appalachian vs. Non-Appalachian 
disparities in the epidemiology of HCV infection. The study utilized data obtained from 
the first statewide study ever conducted in Kentucky to assess the risk factors associated 
with HCV infection. The purpose of this study was to examine the risk factors related to 
HCV infection in Kentucky, and specifically to test the hypothesis that HCV infection 
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would be more prevalent among residents of Appalachian Kentucky compared to those 
residing in Non-Appalachian Kentucky.  
 
 
MATERIALS AND METHODS 
Study Design and Population 
The Kentucky Adult Viral Hepatitis Prevention Coordinator (KY-AVHPC) 
established the Kentucky Viral Hepatitis Coalition, a multidisciplinary team that includes 
Kentucky Department for Public Health (KDPH) staff, infection preventionists, and 
regional epidemiologists from local health departments, substance abuse treatment center 
program managers, KY Department of Corrections medical director, Kentucky Primary 
Care Association director, primary care providers and networks, and hepatologists and 
infectious disease specialists for the treatment of viral hepatitis in Lexington and 
Louisville.  
Kentucky received permission in April 2012 to conduct a pilot laboratory testing 
project for HCV infection in 37 selected local health departments (LHD) jurisdictions. 
LHDs were given guidelines for screening and obtaining blood samples from high-risk 
individuals for HCV antibody and RNA testing to determine those exposed to HCV 
infection. Data was also administered through interview-administered questionnaires. The 
eligibility criteria for the pilot study included being at least 18 years of age, a resident of 
Kentucky, history of IDU, lifetime history of multiple sexual partners, or lifetime history 
of STD. Patients presenting with active liver disease of any cause were excluded from the 
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study. This pilot project lasted from May 1, 2012 to October 31, 2014. This compiled data 
were reported to the Viral Coordinator at KDPH. 
By the end of the study, 8300 high-risk individuals underwent interview-
administered questionnaires and had blood samples drawn at the same time at different 
substance abuse clinics, STD clinics, rehabilitation centers, and other treatment centers 
within local health departments. The dried blood sample specimens collected by finger 
stick were submitted to the Kentucky State Public Health Laboratory for analysis. This 
analysis focused on screening the participants for the presence of anti-HCV antibodies 
using an enzyme immunoassay (EIA) test (sensitivity: 91.8%; specificity 98.2%) 
(Chernesky et al., 2001). Blood specimens from those with anti-HCV antibodies were 
referred to one of two national reference laboratories (Quest Diagnostics or LabCorp – KY) 
to carry out the HCV RNA confirmatory test using the recombinant immunoblot assay 
(RIBA) test from May 2012 to mid-June 2013 and the quantitative real-time polymerase 
chain reaction (PCR) RNA test from mid-June 2013 to October 2014. During the transition 
from RIBA to PCR testing, RNA testing was not performed for an unknown number of 
HCV antibody positive specimens, and also the sensitivity and specificity differed between 
the RIBA and PCR tests; thus, limiting reliable aggregation of the results. Therefore, RNA 
results were excluded from this analysis.  
 At the start of the pilot study, the KDPH did not have a Viral Hepatitis Coordinator 
employed to receive the completed questionnaires and test results. In addition, the State 
Laboratory could store data for only 6 months. As a result, most of the initial data collected 
in the first 6 months of the pilot study were lost.  By the end of the study, the total compiled 
data at KDPH included 5300 completed questionnaires and test results. Of the 5300, 29 
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were tests performed on individuals who resided outside of Kentucky and 66 surveys were 
missing responses from all the behavioral survey questions and part of the demographic 
survey questions. Thus, these were excluded from analysis, leaving a final sample size of 
5205.  
 
Questionnaire Survey and Data Collection 
The interviewer-administered questionnaires were developed by the KDPH, based 
on knowledge of potential risk factors associated with HCV infection and with the guidance 
and advice from regulatory officials and viral hepatitis coordinators working in other states. 
A trained staff member at each center or local health department interviewed the high-risk 
individuals using the questionnaire to obtain information on socio-demographics (age, 
gender, race, ethnicity, and home address zip code), risk behavior (MSM, lifetime history 
of multiple sexual partners, history of IDU, and presence of tattoos), and medical history 
(HIV status and lifetime history of STD). The hard copy completed surveys were sent to 
the Viral Hepatitis Coordinator at the KDPH. This information and test results were 
compiled in Microsoft Excel 2013 software. 
 
Statistical Analysis 
 SPSS, version 22 (IBM Corp) were used for the analysis and ArcGIS mapping 
software was used to create maps. Descriptive statistics were reported as frequency and 
percentages for categorical variables; and as means and standard deviations for continuous 
variables. The only continuous variable in this study was age. The categorical variables 
included gender, race, ethnicity, history of IDU, lifetime history of multiple sex partners, 
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MSM, lifetime history of STD, presence of tattoos, self-reported HIV status, and residence 
in an Appalachian or Non-Appalachian county. Residential address zip codes were used to 
determine whether or not participants resided in a county designated by the Appalachian 
Regional Commission to be in an Appalachian region versus Non-Appalachian region 
(ARC, 2015). The HCV prevalence by county was graphically represented in Figure 1. 
 Univariate and bivariate descriptive analyses were conducted to assess the 
association between each independent variable (described above) with the outcome of 
interest (HCV antibody status). Descriptive statistics are presented by HCV antibody status 
in Table I.  Logistic regression analysis was carried out to compute the crude odds ratio 
and 95% confidence interval for the variables. Statistical significance was determined 
using criteria of p-value <0.05. This is presented in Table I.  
The next steps in the analysis used modeling to examine the association between 
residence in Appalachian vs. Non-Appalachian counties and HCV antibody status. A 
summary of the statistical analyses is also found under the Appendix section.  
Collinearity assessment. All the variables were put into a linear model to compute 
tolerance and variance inflation factor (VIF) to assess for collinearity. Collinearity would 
be present with a VIF >10 and Tolerance <0.10 (Belsley et al., 2005).  
Interaction assessment. Cross-tabulation for each variable by HCV antibody status 
and residence in Appalachian vs. Non-Appalachian county was carried out to identify strata 
with cell sizes too small (i.e. cell sizes of zero) to be analyzed in interaction terms reliably. 
The variables with zero cells were excluded when assessing for interaction. Logistic 
regression analysis was carried out to compute the odds ratio (OR) for each interaction 
term’s association with HCV antibody status, adjusted for lower-order terms. If the 
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statistical significance using p-value <0.05 was found, the interaction term was kept for the 
final model.  
Confounding assessment. All of the independent variables were assessed for 
confounding using a 15% change criteria (Bursac et al., 2008) between the estimated crude 
odds ratio obtained from the stated association (residence and HCV antibody status) and 
the adjusted odds ratio obtained after adjusting for each variable as a potential confounder. 
If the difference between the two measures of association was 15% or greater, then the 
variable was considered a confounder and kept for the final model.  
Multivariable analysis. The first multivariable logistic regression model included 
the exposure variable (residence in Appalachia vs. Non-Appalachian region), all 
confounding variables, interaction terms and their lower order terms, and the remaining 
independent variables that were significantly associated with HCV seropositivity in the 
univariate analysis in Table I. All 12 variables were run in a linear regression model to 
reassess for collinearity using tolerance and VIF values. A final model examining the 
variables associated with HCV antibody status was determined using backward elimination 
logistic regression analysis. Backward elimination was used to sequentially remove all 
variables with the highest p-values above the significant p-value <0.05, leaving only the 
statistically significant variables in the final model including the confounders and 
interaction terms. The adjusted odds ratio and 95% confidence intervals were computed 
for the remaining variables in the final model using multivariable logistic regression. 
Results are presented in Table II.  
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Stratified analysis by region of residence. Logistic regression analysis was carried 
out to assess the variables significantly associated with HCV antibody status in 
Appalachian and Non-Appalachian counties. This was presented in Table III.  
 
Ethics Statement 
This study was approved by the Institutional Review Board of the KDPH (CHFS-
IRB-DPH-FY15-26) and the Institutional Review Board of University of Kentucky (15-
0290-P3H). Informed consent was obtained from all participants in the initial pilot study. 
 
 
RESULTS 
Univariate and Bivariate Analyses of Socio-demographic and Behavioral Factors  
Of the 5205 participants included in the analysis, 509 (9.8%) tested positive for 
antibodies against HCV and 4696 (90.2%) were negative. Data from this study covered 62 
out of the 120 counties in Kentucky, including 17 out of 54 total Appalachian counties and 
45 out of 66 total Non-Appalachian counties. In the sample, 209 (4.0%) resided in 
Appalachian counties and 4996 (96.0%) in Non-Appalachian counties. Of the 509 
individuals who tested HCV positive, 28 (5.5%) resided in Appalachian counties and 481 
(94.5%) in Non-Appalachian counties. Figure 1 demonstrates that the HCV positive 
individuals were concentrated in the Northern part of the state, even though the 
participating counties in the study were scattered throughout the state.  A total of 37 out of 
the 62 participating counties did not report any HCV positive case (grey-colored areas). 
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The map also demonstrates that many Appalachian and Non-Appalachian counties did not 
participate in the study (white-colored).  
Table 1 describes demographic and behavioral characteristics. The mean age of the 
HCV positive individuals was 31.9 ± 10.2 years and for HCV negative individuals, 
30.2 ± 10.6 years. Approximately 43% of the participants were male. The majority (76%) 
of the sample was White, 24% Black, and <1% “other” races, which in this study included 
Asian and Mixed races. The participants in this study were mostly (94%) Non-Hispanic. 
Overall, 14% reported a history of IDU and they accounted for 78.0% of those testing HCV 
positive; 5% reported being HIV positive and 10% of those were HCV positive. 
Interestingly, among MSM in the study (5% of the sample), 2.2% were HCV positive with 
an odds ratio of 0.44 (95% CI: 0.24-0.80). The variables that were not significantly 
associated with HCV antibody status included gender (p=0.062), “Other” race (p = 0.152), 
lifetime history of STD (p = 0.812), and residence in Appalachian vs. Non-Appalachian 
counties (p = 0.074).  
 
Relationship between Appalachian versus Non-Appalachian Residence and HCV 
Antibody Seropositivity 
Gender was determined to be an effect modifier (interaction term OR: 2.55, 95% 
CI: 1.11 – 5.88, p-value = 0.028). This indicates that for males in the study, the effect of 
residing in Appalachian counties on HCV seropositivity is more pronounced than for 
females residing in Appalachian counties. Results from the confounding assessment (Table 
VI in Appendix) demonstrated that the strength of the association between residence in 
Appalachia and HCV antibody status (crude OR: 1.45, 95% CI: 0.97 – 2.19) was decreased 
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by the presence of two confounding variables: race (AOR: 1.20, 95% CI: 0.79 – 1.81), and 
HIV status (AOR: 1.22, 95% CI: 0.75 – 1.96). The strength of the association between 
residence in Appalachia and HCV antibody status was increased by the presence of two 
confounding variables: history of IDU (AOR: 1.96, 95% CI: 1.14 – 3.37), and history of 
multiple sexual partners (AOR: 1.70, 95% CI: 1.12 – 2.58). In other words, this indicates 
that race and HIV status each minimize the association between residence in Appalachian 
vs. Non-Appalachian and HCV antibody status by biasing the measure of association 
towards the null, whereas history of IDU and history of multiple sexual partners each 
exaggerate the association between residence in Appalachian vs. Non-Appalachian 
counties and HCV antibody status as the effect estimate is biased away from the null.  
During backward elimination, history of previous STD was removed first, followed 
by ethnicity. The final model, presented in Table II, included confounders (listed above), 
interaction terms and their lower order terms, and other statistically significant variables 
remaining after backward elimination. Adjusting for all the other variables in the model, 
significant associations were observed between HCV seropositivity and Black race (AOR: 
0.42, 95% CI: 0.26 – 0.66), age (AOR: 1.03, 95% CI: 1.02 – 1.04), history of IDU (AOR: 
41.27, 95% CI: 31.94 – 53.31), MSM (AOR: 0.36, 95% CI: 0.17 – 0.73), and presence of 
tattoos (AOR: 1.49, 95% CI: 1.14 – 1.96). There was no significant association between 
HCV antibody status and residence in Appalachian vs. Non-Appalachian counties, gender, 
HIV status, history of multiple sexual partners, and “other” races compared to White race. 
Interestingly, adjusting for all the variables in the final model, the odds of being HCV 
positive was lower among MSM compared to non-MSM. In addition, the odds of being 
HCV positive was lower in the Blacks compared to the Whites. 
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When models were stratified by residence in Appalachian and Non-Appalachian 
regions, interesting patterns emerged. Table III displays correlates associated with HCV 
infection among Appalachian and Non-Appalachian residents. Gender, history of IDU and 
history of multiple sexual partners were the only factors found to be significantly associated 
with HCV antibody status among residents in Appalachian counties. However, age, race, 
ethnicity, HIV status, presence of tattoos, MSM, history of IDU and history of multiple 
sexual partners were found to be significantly associated with HCV antibody status among 
residents of Non-Appalachian counties. Of note, none of the independent variables were 
found to be collinear, as all values for VIF were < 2 and Tolerance were > 35.  
 
 
DISCUSSION 
In this analysis, the association between residence in Appalachian vs. Non-
Appalachian counties and HCV antibody status was not statistically significant. However 
several factors were found to influence the association. Race, history of IDU, HIV status, 
and history of multiple sexual partners were found to confound the association between 
residence in Appalachian vs. Non-Appalachian counties and HCV antibody status. In the 
final model, adjusting for confounders, MSM was associated with decreased odds of HCV 
infection, whereas presence of tattoos and age were associated with increased odds of HCV 
infection. Of note, the variables associated with HCV seropositivity differed between the 
geographic regions of Kentucky. For example, gender was associated with HCV infection 
among Appalachian residents, with males having higher risk, but not associated with HCV 
infection among Non-Appalachian residents. Race and MSM were associated with HCV 
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infection among Non-Appalachian residents, with Black race and MSM having lower risk, 
but were not associated with HCV infection among Appalachian residents. Age and 
presence of tattoos were also associated with HCV infection among Non-Appalachian 
residents, with age and presence of tattoos having higher risk, but were not associated with 
HCV infection among Appalachian residents. History of IDU was associated with HCV 
among Appalachian and Non-Appalachian residents, with a slightly higher risk in 
Appalachian residents compared to Non-Appalachian residents.  
Results from the present study (Table II) demonstrated that for every one year 
increase in age, the odds of HCV infection increased by 1.03, while holding all other 
variables constant. In this study, the 20-29 age group accounted for the most HCV cases, 
with 247 (48.5%) out of the total 509 HCV positive individuals. This finding is consistent 
with previous studies, which have indicated that peak prevalence of HCV infection in the 
US is observed among people aged 20-29 years of age (CDC, 2015). Of note, when the 
data in the present study were stratified by gender, the positive association between age 
and HCV infection was significant among males but not females.  
The current study also found that the HCV prevalence was highest among White 
race. This observation was similar to results obtained from the MMWR by Zibbell and 
colleagues (2015), whereby non-Hispanic Whites have a greater HCV prevalence 
compared to non-Hispanic Blacks. Another study had reported an epidemic of HCV 
infection in the US predominantly among Whites less than 30 years of age, residing in 
Appalachian counties east of the Mississippi River (Suryaprasad et al., 2014). Compared 
to the White population in the present study, Blacks residing in Non-Appalachian counties 
appeared to have a protective effect in being HCV positive. 
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Gender was found to modify the association between residence in Appalachian vs. 
Non-Appalachian counties and HCV antibody status. In crude analysis of interaction, the 
association between being male and HCV positive was higher among Appalachian 
residents compared to Non-Appalachian residents. Males in Appalachia had nearly three 
times higher odds of being HCV positive than females, while males in Non-Appalachia did 
not have significantly higher odds of being HCV positive than females. This difference 
between males and females influencing the effect of HCV seropositivity can be explained 
by previous studies that demonstrated that rates of HCV infection differ significantly 
between gender owing to the different behavioral risks undertaken by men and women. 
Research has shown that women tend to engage more in sexually-related risk behaviors 
including having unprotected sex in exchange for money or drugs, whereas men tend to 
engage in lifetime drug-related risk behaviors including needle sharing, and illicit drug use 
such as crack cocaine (Butterfield et al., 2003).  
IDU is one of the most important risk factors for HCV infection, especially among 
young PWID (Alter, 2007). The results of this study supported those findings; the odds of 
being HCV positive among those with a history of IDU was over forty-one times higher 
than those without a history of IDU, after adjusting for the other variables in the model. In 
addition, history of IDU was found to be associated with HCV infection among residents 
in Appalachian and Non-Appalachian counties. These findings were consistent with other 
studies, which suggested that HCV infection in Appalachian counties is highly associated 
with PWID (Christian et al., 2010; Havens et al., 2013; Zibbell et al., 2015). Notably, 
results from Young and colleagues (2013) indicated that turnover in individuals’ injection 
networks (i.e. injecting with different individuals over time) in Appalachian Kentucky 
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inferred a protective effect of HCV infection. Nonetheless, the increased rates of HCV 
infections in Kentucky are likely associated with the prescription opioid epidemic among 
PWID in Appalachia (Havens et al., 2013; Young et al., 2012).  
Presence of tattoos as a possible risk factor for HCV infection has been researched 
in previous studies. Some of these studies have shown an association between tattooing 
and increased risk of HCV infection in unregulated settings where tattooing needles are 
reused (Hwang et al., 2006), commercial tattoo parlors (Haley and Fischer, 2001), and 
among high-risk groups such as incarcerated population where needles are shared and 
reused (Hwang et al., 2006; Tohme and Holmberg, 2012), whereas other studies have failed 
to produce a similar association (Hahn et al., 2001). This has been because the tattoo 
measurement has varied between studies, with some studies distinguishing tattooing from 
ear piercing and body piercing (Alter, 2002; Hahn et al., 2001; Hwang et al., 2006). Tattoos 
in the present study were defined as presence of ink markings on the skin. In this study, 
people who had a tattoo were 1.49 times the odds of having HCV infection compared to 
those who did not have HCV infection after adjusting for the other variables in the model. 
Notably, presence of tattoos was found to be significantly associated with HCV infection 
only in Non-Appalachian counties in the state. However, information on the type and 
location of the tattoos, as well as the environment and expertise of the person imprinting 
the tattoos were not examined, but might be worthy of investigation in future studies. 
Moreso, because this observation has been identified mostly in cross-sectional studies 
(Alter, 2002; Haley and Fischer, 2001) that do not provide a temporal relationship between 
tattoo exposure and HCV infection, a true causal relationship cannot be made. 
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The study analysis showed that MSM have decreased odds of HCV seropositivity, 
specifically in Non-Appalachian counties. Some studies (Buchbinder et al., 1994; McFaul 
et al., 2014) have indicated that HCV infection is mostly found among MSM injecting 
drugs and engaging in sexual activity with multiple partners. There has also been a strong 
association between HCV infection and HIV-infected MSM (Workowski and Berman, 
2010). This protective effect in this study could be due to increased awareness among these 
population resulting in less people engaging in risk behaviors including IDU and 
unprotected high-risk sexual practices. More so, this observation could be due to the small 
MSM population size (n=237) in this study, of which, a smaller fraction of 11 (2.2%) tested 
positive for anti-HCV antibodies. This small sample size provided a low statistical power 
to detect the true effect. In addition, because the entire sample was composed of high-risk 
individuals, the MSM population was being compared to other high-risk groups such as 
PWID instead of the general population, which would affect its measure of association with 
HCV infection (i.e. MSM are at lower risk of HCV infection compared to PWID). More 
research is required to improve understanding of HCV transmission and measures currently 
undertaken by MSM to reduce HCV infection risk.   
Sexual transmission of HCV is uncommon, except among MSM (Workowski and 
Berman, 2010). The risk of sexual transmission of HCV among monogamous couples has 
been determined to be extremely rare (Karmochkine et al., 2006; Marian et al., 2003; 
Rustgi, 2007). Results from Armstrong and colleagues (2006) indicate that having greater 
than 20 lifetime sexual partners has been significantly associated with HCV seropositivity 
in the US after controlling for age and sex, as it increases the risk of HCV infection by 
fourfold. According to results from this study, having a history multiple sexual partners 
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was not significantly associated with HCV infection in the univariate analysis or in the 
final model. However, when stratified by the residence in Appalachian vs. Non-
Appalachian counties, history of multiple sexual partners was found to be independently 
associated with HCV infection among residents in both Appalachian and Non-Appalachian 
counties. This difference could be explained by the fact that adequate data was not available 
on the number of sexual partners engaging in particular high-risk behaviors (i.e., data were 
only available on whether or not they had multiple partners, not how many partners and the 
risk behavior of those partners). Takeuchi and colleagues (2015) had indicated that having 
HCV-infected sexual partners was significantly associated with HCV seropositivity among 
men, and not among females. Interestingly, the association between multiple sexual 
partners and HCV seropositivity in this study was significant only among females and not 
among men for unknown reasons. Further studies are required to elucidate the association 
of sexual risk behavior among men and women. 
 
Limitations 
The study had several limitations. First, data collected from the surveys was based 
on self-reported behaviors. This study assumes that the information provided by the 
participants was accurate and valid. However, self-reported information introduces biases 
such as recall bias and information bias, specifically misclassification bias that results in 
residual confounding. Second, being a cross-sectional study, previous exposure history to 
the different factors does not infer causality of the HCV infection. These factors cannot be 
said to cause HCV infection over time. Third, the presence of values less than 5 and missing 
data in some cells in the contingency tables may impact the statistical power to detect  
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associations during the stratified analysis. Fourth, selection bias may have occurred, given 
that only high-risk individuals at particular centers were selected as the study population. 
Fifth, 37 LHD testing sites were invited to participate; only 30 participated in this study, 
suggesting that the results may not be representative of all counties in the state, especially 
if the non-participating counties had a high prevalence of HCV infection, thereby affecting 
the external validity of the study. Lastly, this study used only HCV antibody test results, 
whereby an HCV antibody positive result meant having been infected with HCV at some 
point in the past. HCV antibody status provides no information on the active or chronic 
state of the infection. 
 
Public Health Implications  
The results from this study highlight opportunities for public health programs. Of 
note, many counties did not participate in the cross-sectional study due to lack of resources 
to carry out the HCV testing and questionnaires. Programs are thereby needed to increase 
resources in those counties with insufficient resources in order to foster participation in 
future HCV studies and conduct HCV surveillance. In addition, gender-specific preventive 
interventions tailored towards particular geographic regions, specifically men in rural 
Appalachia, can help decrease the prevalence of HCV infection in Kentucky. National 
health survey data indicate that approximately 50% of HCV-infected persons in the US 
have been tested for HCV, and that only 6% of those tested receive adequate treatment 
(Davis et al., 2011; Munir et al., 2010). This demands implementation of primary 
prevention programs, including education to professional and public institutions, effective 
screening and risk-reduction counseling of high-risk individuals, referral of care to 
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substance abuse treatment clinics and hospitals to improve access and increase the 
proportion of high-risk individuals receiving treatment, as recommended by CDC (1998). 
Reports from CDC (1998) indicate that secondary prevention measure can reduce the risk 
of developing the long-term complications of HCV infection by identifying HCV positive 
people and providing appropriate medical treatment and management. This also requires 
early placement on the liver transplantation list for those with advanced liver disease.  
There is an urgent need to enroll high-risk young adults into substance abuse 
treatments and treatment facilities. Such undertaking requires collaboration between 
federal organizations such as CDC, working with the state and local health departments to 
implement measures to address the parenteral prescription drugs epidemic and HCV 
infection. Any intervention to decrease the rates of HCV infection should include educating 
different age groups on safe sexual practices, targeting different tattoo parlors, and 
increasing the number of needle exchange programs, which targets the PWID. Alter (2002) 
had indicated that an effective prevention measure to reduce HCV infection among PWID 
would be to nullify the restrictive paraphernalia regulation and increase the number of 
needle exchange programs whereby sterile syringes and needles can be made available to 
this population. Implementation of needle exchange programs has also be shown to be 
effective not only in reducing transmission of HCV infection, but also HCV incidence in 
PWID (Des Jarlais et al., 2009; Van Den Berg et al., 2007). Recently, the anti-heroin 
legislation (Senate Bill 192) was passed in Kentucky allowing health departments in the 
state of Kentucky to establish needle exchange programs where people who use drugs can 
exchange their used needles and syringes for clean ones, and also for the state to increase 
access to treatment for this population (Cheves, 2015; Wynn, 2015).  
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CONCLUSION 
In conclusion, this study showed that age and MSM, history of IDU and presence 
of tattoos influenced the association between residence in Appalachia vs. Non-Appalachia 
and HCV infection in the state of Kentucky. Furthermore, risk factors differ between the 
geographic regions of Kentucky. Therefore, reinforced public education and intervention 
targeting different gender groups and risky behaviors are required to prevent HCV 
infection in the state. Despite the limitations of this study, information was provided on 
some risk factors associated with the high prevalence of HCV infection in Kentucky and 
the study also highlighted the distribution of HCV infection and its significant associated 
variables depending on the region of residence. More research is required to provide a 
better understanding of the association between these risky behaviors and HCV infection. 
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TABLES AND FIGURES 
 
Table I. Descriptive and Bivariate Analyses of Factors Associated with HCV Antibody 
Status 
 
Risk factors Total 
(n=5205) 
Anti-HCV 
Positive 
(n=509) 
Anti-HCV 
Negative 
(n=4696) 
Unadjusted OR 
(95% CI) 
P-
value  
N (%) N (%) N (%) 
Gender 
       Female 
       Male 
 
2964 (56.9) 
2241 (43.1) 
 
270 (53.0) 
239 (47.0) 
 
   2694 (57.4) 
   2002 (42.6) 
 
reference 
  1.19 (0.99-1.43) 
 
− 
0.062 
Race 
       White 
       Black 
       Othersa 
 
3952 (75.9) 
1221 (23.5) 
  32 (0.6) 
 
481 (94.5) 
27 (5.3) 
  1 (0.2) 
 
3471 (73.9) 
1194 (25.4) 
  31 (0.7) 
 
reference 
  0.16 (0.11-0.24) 
  0.23 (0.03-1.71) 
 
− 
0.000 
0.152 
Ethnicity 
       Hispanic 
       Non-Hispanic 
 
297 (5.7) 
4908 (94.3) 
 
  6 (1.2) 
503 (98.8) 
 
291 (6.2) 
4405 (93.8) 
 
reference 
  5.54 (2.46-12.49) 
 
− 
0.000 
Age (years),  
       mean (SD) 
 
   30.4 (10.5) 
 
31.9 (10.2) 
 
 30.2 (10.6) 
 
  1.02 (1.01-1.02) 
 
0.000 
Hx of IDU 
       No 
       Yes 
 
4487 (86.2) 
  718 (13.8) 
 
112 (22.0) 
397 (78.0) 
 
4375 (93.2) 
321 (6.8) 
 
reference 
48.31 (38.07-61.32) 
 
− 
0.000 
HIV Status 
       Negative 
       Positive 
       Unawareb 
 
4740 (91.1) 
276 (5.3) 
189 (3.6) 
 
430 (84.5) 
  51 (10.0) 
28 (5.5) 
 
4310 (91.8) 
225 (4.8) 
161 (3.4) 
 
reference 
2.27 (1.65-3.13) 
1.74 (1.15-2.64) 
 
− 
0.000 
0.008 
Hx Multiple sexual 
partners 
       No 
       Yes 
 
 
1086 (20.9) 
4119 (79.1) 
 
 
  67 (13.2) 
442 (86.8) 
 
 
1019 (21.7) 
3677 (78.3) 
 
 
reference 
1.83 (1.40-2.39) 
 
 
− 
0.000 
MSMc 
       No 
       Yes 
 
4957 (95.2) 
237 (4.6) 
 
498 (97.8) 
11 (2.2) 
 
4459 (95.0) 
226 (4.8) 
 
reference 
0.44 (0.24-0.80) 
 
− 
0.008 
Tattoosd 
       No 
       Yes 
 
2057 (39.5) 
3078 (59.1) 
 
121 (23.8) 
381 (74.8) 
 
1936 (41.2) 
2697 (57.4) 
 
reference 
2.26 (1.83-2.80) 
 
− 
0.000 
Previous STDc 
       No 
       Yes 
 
2925 (56.2) 
2269 (43.6) 
 
283 (55.6) 
224 (44.0) 
 
   2642 (56.3) 
   2045 (43.5) 
 
reference 
1.02 (0.85-1.23) 
− 
0.812 
Regional Residence 
   Non-Appalachian 
       Appalachian 
 
4996 (96.0)   
209 (4.0) 
 
481 (94.5) 
28 (5.5) 
 
4515 (96.1) 
181 (3.9) 
 
reference 
1.45 (0.97-2.19) 
 
− 
0.074 
SD =standard deviation, Hx = history, IDU = injection drug use, MSM = men who have sex with 
men, STD= sexually transmitted diseases, KY = Kentucky, 95% CI = 95% confidence interval 
 a Others include Asian and mixed race 
 b Participants either did not know their status or that information was missing  
 c 11 participants had missing data for these variables 
 d 70 participants had missing data for this variable 
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Table II. Final Multivariate Logistic Regression Model Examining Variables Associated 
with HCV Antibody Seropositivity 
 
Variables Adjusted OR  95% Confidence 
Interval (CI) 
P-value 
Regional Residence 
       Non-Appalachian 
       Appalachian 
 
reference 
1.16 
 
− 
0.52-2.62 
 
− 
0.713 
Gender 
       Female 
       Male 
 
reference 
1.16 
 
− 
0.90-1.48 
 
− 
0.254 
Race 
       White 
       Black 
       Othersa 
 
reference 
0.42 
0.69 
 
− 
0.26-0.66 
0.08-6.37 
 
− 
  0.000* 
0.744 
Age (years) 1.03 1.02-1.04   0.000* 
Hx of IDU 
       No 
       Yes 
 
reference 
41.27 
 
− 
31.94-53.31 
 
− 
  0.000* 
HIV Status 
       Negative 
       Positive 
       Unawareb 
 
reference 
1.37 
0.99 
 
− 
0.89-2.11 
0.50-1.95 
 
− 
0.153 
0.977 
Hx Multiple sexual 
partners 
       No 
       Yes 
 
 
reference 
1.31 
 
 
− 
0.94-1.83 
 
 
− 
0.110 
MSMc 
       No 
       Yes 
 
reference 
0.36 
 
− 
0.17-0.73 
 
− 
  0.005* 
Tattoosd 
       No 
       Yes 
 
reference 
1.49 
 
− 
1.14-1.96 
 
− 
  0.004* 
Appalachian*Gender 2.52 0.78-8.19 0.124 
Likelihood Ratio Chi-Square = 1360.076, on 12 df; p-value = 0.000 
SD = standard deviation, Hx= history, IDU= injection drug use, MSM= men who have sex with 
men 
*Indicates statistical significance (p<0.05) 
 a Others include Asian and mixed race 
 b Participants either did not know their status or that information was missing  
 c 11 participants had missing data for this variable 
 d 70 participants had missing data for this variable 
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Table III. Variables Associated with HCV Antibody Seropositivity Stratified by 
Appalachian and Non-Appalachian Residence 
 
Variables Appalachian (n=209) Non-Appalachian  (n=4996) 
OR (95% CI) P-value OR (95% CI) P-value 
Gender 
       Female 
       Male 
 
reference 
2.94 (1.30-6.62) 
 
− 
0.009 
 
reference 
1.15 (0.95-1.39) 
 
− 
0.147 
Race 
       White 
       Black 
       Othersa 
 
reference 
0.00 (0.00) 
− 
 
− 
0.999 
− 
 
reference 
0.17 (0.11-0.25) 
0.24 (0.03-1.73) 
 
− 
0.000 
0.155 
Ethnicity 
       Hispanic 
       Non-Hispanic 
 
reference 
− 
 
− 
− 
 
reference 
  5.45 (2.42-12.31) 
 
− 
0.000 
Age (years) 1.00 (0.96-1.04) 0.904 1.02 (1.01-1.02) 0.000 
Hx of IDU 
       No 
       Yes 
 
reference 
54.06 (18.29-159.80) 
 
− 
0.000 
 
reference 
48.67 (38.07-62.21) 
 
− 
0.000 
HIV Status 
       Negative 
       Positive 
       Unawareb 
 
reference 
 2.97 (0.28-31.06) 
     1.78 (0.78-4.06) 
 
− 
0.363 
0.169 
 
reference 
2.26 (1.64-3.13) 
1.49 (0.81-2.75) 
 
− 
0.000 
0.204 
Hx Multiple 
sexual partners 
       No 
       Yes 
 
 
reference 
2.97 (1.20-7.32) 
 
 
− 
0.018 
 
 
reference 
1.82 (1.37-2.41) 
 
 
− 
0.000 
MSMc 
       No 
       Yes 
 
reference 
 2.20 (0.22-21.90) 
 
− 
0.502 
 
reference 
0.41 (0.22-0.77) 
 
− 
0.006 
Tattoosd 
       No 
       Yes 
 
reference 
2.05 (0.86-4.89) 
 
− 
0.104 
 
reference 
2.29 (1.84-2.86) 
 
− 
0.000 
Previous STDc 
       No 
       Yes 
 
reference 
1.45 (0.63-3.36) 
 
− 
0.381 
 
reference 
1.01 (0.84-1.22) 
 
− 
0.916 
OR = odds ratio, SD =standard deviation, Hx = history, IDU = injection drug use, MSM = men 
who have sex with men, STD= sexually transmitted diseases, KY = Kentucky, 95% CI = 95% 
confidence interval 
 a Others include Asian and mixed race 
 b Participants either did not know their status or that information was missing  
 c 11 participants had missing data for these variables 
 d 70 participants had missing data for this variable 
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Figure 1. Distribution of HCV positive individuals by county in Kentucky, 2012-2014 
(n=5205). The different shades of purple indicate the counties with HCV positive 
individuals in increasing numbers. The counties with the highest HCV prevalence are 
concentrated in Northern Kentucky. The gray-colored regions include counties that 
participated in the statewide survey study but reported no HCV positive individuals. The 
white-colored counties include those counties that did not participate in the statewide study. 
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APPENDIX 
 
Table IV. Distribution of Variables between Appalachian versus Non-Appalachian 
County Residence: Results of Bivariate Analysis 
 
Variables Appalachian (n=209) Non-Appalachian  (n=4996) 
HCV+, N (%) HCV-, N (%) HCV+, N (%) HCV-, N (%) 
Gender 
       Female 
       Male 
 
14 (50.0) 
14 (50.0) 
 
     135 (74.6) 
46 (25.4) 
 
256 (53.2) 
225 (46.8) 
 
2559 (56.7) 
1956 (43.3) 
Race 
       White 
       Black 
       Othersa 
 
  28 (100.0) 
0 (0.0) 
0 (0.0) 
 
     168 (92.8) 
       13 (7.2) 
0 (0.0) 
 
453 (94.2) 
27 (5.6) 
  1 (0.2) 
 
3303 (73.2) 
1181 (26.2) 
  31 (0.7) 
Ethnicity 
       Hispanic 
       Non-Hispanic 
 
0 (0.0) 
  28 (100.0) 
 
0 (0.0) 
181 (100.0) 
 
  6 (1.2) 
475 (98.8) 
 
291 (6.4) 
4224 (93.6) 
Age (years),  
       mean (SD) 
 
     30.0 (6.0) 
 
    30.0 (11.0) 
 
32.0 (10.0) 
 
 30.0 (11.0) 
Hx of IDU 
       No 
       Yes 
 
 8 (28.6) 
20 (71.4) 
 
     173 (95.6) 
8 (4.4) 
 
104 (21.6) 
377 (78.4) 
 
4202 (93.1) 
313 (6.9) 
HIV Status 
       Negative 
       Positive 
       Unawareb 
 
11 (39.3) 
1 (3.6) 
16 (57.1) 
 
98 (54.1) 
3 (1.7) 
80 (44.2) 
 
419 (87.1) 
  50 (10.4) 
12 (2.5) 
 
4212 (93.3) 
222 (4.9) 
  81 (1.8) 
Hx Multiple 
sexual partners 
       No 
       Yes 
 
 
 7 (25.0) 
21 (75.0) 
 
 
90 (49.7) 
91 (50.3) 
 
 
  60 (12.5) 
421 (87.5) 
 
 
  929 (20.6) 
3586 (79.4) 
MSMc 
       No 
       Yes 
 
27 (96.4) 
1 (3.6) 
 
     178 (98.3) 
3 (1.7) 
 
471 (97.9) 
10 (2.1) 
 
4281 (95.0) 
223 (5.0) 
Tattoosd 
       No 
       Yes 
 
  9 (36.0) 
16 (64.0) 
 
97 (53.6) 
84 (46.4) 
 
112 (23.5) 
365 (76.5) 
 
1839 (41.3) 
2613 (58.7) 
Previous STDc 
       No 
       Yes 
 
15 (57.7) 
11 (42.3) 
 
     119 (66.5) 
60 (33.5) 
 
268 (55.7) 
213 (44.3) 
 
2523 (56.0) 
1985 (44.0) 
SD =standard deviation, Hx = history, IDU = injection drug use, MSM = men who have sex with 
men, STD= sexually transmitted diseases, KY = Kentucky 
 a Others include Asian and Mixed race 
 b Participants either did not know their status or that information was missing  
 c 11 participants had missing data for these variables 
 d 70 participants had missing data for this variable 
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Table V. Assessing Interaction in the Association between Appalachian versus Non-
Appalachian Residence and HCV Antibody Seropositivity: Results of Bivariate Analysis 
Variablesa OR 95% CI P-value 
Appalachiane  1.45 0.97-2.19 0.074 
Appalachian*Gender  2.55 1.11-5.88   0.028* 
Appalachian*Age (years) 0.98 0.95-1.02 0.371 
Appalachian*Hx of IDU  1.11 0.37-3.38 0.853 
Appalachian*HIV status b 0.85 0.54-1.35 0.495 
Appalachian*Hx Multiple sexual 
partners 
1.63 0.63-4.20 0.310 
Appalachian*MSMc 5.39 0.50-58.65 0.166 
Appalachian*Tattoosd 0.90 0.37-2.19 0.808 
Appalachian*Previous STDc 1.44 0.61-3.40 0.405 
Hx = history, IDU = injection drug use, MSM = men who have sex with men, STD= sexually 
transmitted diseases, OR = odds ratio, 95% CI = 95% confidence interval 
*Interaction present 
 a Race and ethnicity variables were excluded because they contained stratified cell sizes too small  
  (i.e. cell sizes of zero) to be analyzed in interaction terms 
 b 189 participants either did not know their status or that information was missing  
 c 11 participants had missing data for these variables 
 d 70 participants had missing data for this variable 
 e Non-Appalachian residence was the reference group 
 
 
Table VI. Assessing Confounding in the Association between Appalachian versus Non-
Appalachian Residence and HCV Antibody Seropositivity: Results of Bivariate Analysis 
Variables OR† 95% CI P-value 
Appalachiana  1.45 0.97-2.19 0.074 
Appalachian + Gender  1.49 0.99-2.25 0.055 
Appalachian + Race   1.20* 0.79-1.81 0.391 
Appalachian + Ethnicity 1.38 0.91-2.07 0.127 
Appalachian + Age (years) 1.47 0.97-2.21 0.067 
Appalachian + Hx of IDU   1.96* 1.14-3.37 0.015 
Appalachian + HIV status b   1.22* 0.75-1.96 0.421 
Appalachian + Hx Multiple sexual 
partners 
  1.70* 1.12-2.58 0.012 
Appalachian + MSMc 1.43 0.95-2.15 0.090 
Appalachian + Tattoosd 1.42 0.92-2.19 0.113 
Appalachian + Previous STDc 1.37 0.90-2.08 0.149 
Hx= history, IDU = injection drug use, MSM= men who have sex with men, STD= sexually 
transmitted diseases, OR = odds ratio, 95% CI = 95% confidence interval 
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*Confounding factors present, as indicated in 15% or greater change in AOR 
 a Non-Appalachian residence was the reference group 
 b 189 participants either did not know their status or that information was missing  
 c 11 participants had missing data for these variables 
 d 70 participants had missing data for this variable 
†Odds ratios are displayed for the association between Appalachian residence and HCV status, 
adjusting for the variable listed in Column 1, where applicable 
 
 
 
Table VII: Socio-demographic Characteristics across Age Groups, 2012-2014 
 Tested (n=5205) Screened HCV+ 
(n=509) 
Screened HCV- 
(n=4696) 
Characteristics N (%) N (%) N (%) 
Age Group (years) 
10-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80+ 
 
459 (8.8) 
2575 (49.5) 
1224 (23.5) 
  566 (10.9) 
302 (5.8) 
  68 (1.3) 
   8 (0.2) 
   3 (0.1) 
 
17 (3.3) 
247 (48.5) 
142 (27.9) 
  60 (11.8) 
38 (7.5) 
  4 (0.8) 
  1 (0.2) 
  0 (0.0) 
 
442 (9.4) 
2328 (49.6) 
1082 (23.0) 
  506 (10.8) 
264 (5.6) 
  64 (1.4) 
    7 (0.1) 
    3 (0.1) 
 
 
 
Table VIII. Association between Variables and HCV Infection Stratified by Gender, 
2012–2014 
Variables Male (n=2241) Female  (n=2964) 
OR (95% CI) P-value OR (95% CI) P-value 
Age (years) 1.02 (1.01-1.03) 0.005 1.01 (1.00-1.02) 0.058 
Hx Multiple 
sexual partners 
       No 
       Yes 
 
 
reference 
1.20 (0.82-1.76) 
 
 
− 
0.342 
 
 
reference 
2.45 (1.69-3.57) 
 
 
− 
0.000 
Hx of IDU 
       No 
       Yes 
 
reference 
49.03 (34.41-69.85) 
 
− 
0.000 
 
reference 
47.57 (34.45-65.68) 
 
− 
0.000 
Hx = history, IDU = injection drug use, OR = odds ratio, 95% CI = 95% confidence interval 
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